Abstract
PCR-based clonality testing can be performed in all lymphoproliferations by analysing gene rearrangements of antigen receptors, rearrangements that are unique for each kind of lymphocyte. Reactive lymphoproliferations have polyclonally rearranged Ig/TCR genes, whereas malignant proliferations (leukaemias and lymphomas) show clonal rearrangements. The aim of this study was to assess the clinical benefits of clonality testing with previously evaluated consensus primers in leukaemia patients. The study included peripheral blood and bone marrow samples of 67 leukaemia patients (32 B-CLL, 24 B-ALL and 11 T-ALL). Clonality testing was based on PCR amplification of rearranged IgH and TCR genes. During diagnosis, monoclonal pattern was found in all analysed B-CLL and T-ALL samples. Testing in B-ALL patients showed positive results in all bone marrow and one peripheral blood samples. Results of clonality testing in B-CLL patients during follow-up were concordant between peripheral blood and bone marrow. Obtained results corresponded to clinical course in all but one patient. In B-ALL group, results of molecular testing in peripheral blood and bone marrow confirmed remission estimated according to clinical criteria in all except one patient. Before any clinical sign of relapse, monoclonal pattern was found in six/seven patients by bone marrow and in three/seven patients by peripheral blood analysis, respectively. Results of molecular monitoring in T-ALL patients did not confirme clinical evaluation in two patients. Obtained results indicate high accuracy of re-evaluated primers for clonality assessment in ALL and CLL patients at the time of diagnosis. Results of clonality testing in B-ALL patients indicate that bone marrow analysis has higher sensitivity compared to analysis of peripheral blood.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abbas A. K. and Lichtman A. H. 2003 Lymphocyte maturation and expression of antigen receptor genes. In Cellular and molecular immunology (ed. A. K. Abbas and A. H. Lichtman), pp. 129–163. Elsevier Science, Philadelphia, USA.
Balduzzi A., Gaipa G., Bonanomi S., Dassi M., Perseghin P., Buscemi F. et al. 2001 Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remissions. Leukemia 15, 50–56.
Braziel R. M., Shipp A., Feldman A. L., Espina V., Winters M., Jaffe E. S. et al. 2003 Molecular diagnostics. Hematology 2003, 279–293.
Cheson B. B., Bennett J. M., Grever M., Kay N., Keating M. J., O’Brien S. and Rai K. R. 1996 National cancer institutesponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87, 4990–4997.
Cikota B., Magić Z., Ilić V., Berger S., Stamatović D. and Malešević M. 2000 B-cell clonality assessment by polymerase chain reaction in patients with B-non Hodgkin’s lymphomas. Balkan. J. Med. Genet. 3, 31–35.
Coustan-Smith E., Sancho J., Hancock M. L., Boyett J. M., Behm F. G., Raimondi S. C. et al. 2000 Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96, 2691–2696.
Dreger P., Ritgen M., Bottcher S., Schmitz N. and Kneba M. 2005 The prognostic impact of minimal residual disease assessment after stem cell transplantation for chronic lymphocytic leukemia: is achievement of molecular remission worthwhile? Leukemia 19, 1135–1138.
Flohr T., Schrauder A., Cazzaniga G., Panzer-Grumayer R., van der Velden V., Fischer S. and International BFM Study Group (IBFM-SG) 2008 Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 22, 771–782.
Gabert J., Beillard E., van der Velden V. H., Bi W., Grimwade D., Pallisgaard N. et al. 2003 Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia — a Europe against cancer program. Leukemia 17, 2318–2357.
Harris N. L., Jaffe E. S., Diebold J., Flandrin G., Muller-Hermelink K. H., Vardiman J. et al. 1999 World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting — Airlie House, Virginia, November 1997. J. Clin. Oncol. 17, 3835–3849.
Kandolf Sekulović L., Cikota B., Stojanović O., Bašanović J., Škiljević D., Medenica Lj. et al. 2007 TCRγ gene rearrangement analysis in skin samples and peripheral blood of mycosis fungoides patients. Acta Dermatovenerol. Alp. Panonica Adriat. 16, 149–155.
Knechtli C. J. C., Goulden N. J., Hancock J. P., Grandage V. L. G., Harris E. L., Garland R. J. et al. 1998 Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia. Blood 92, 4072–4079.
Marshall G. M., Haber M., Kwan E., Zhu L., Ferrara D., Xue C. et al. 2003 Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. J. Clin. Oncol. 21, 704–709.
Piccaluga P. P., Malagola M., Amabile M., Rondoni M., Paolini S., Pane F. et al. 2004 The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. Haematologica 89, 1269–1271.
Provan D., Bartlett-Pandite L., Zwicky C., Neuberg D., Maddocks A., Corradini P. et al. 1996 Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood 88, 2228–2235.
Sambrook J., Fritsch E. F. and Maniatis T. 1989 Preparation of organic reagents. In Molecular cloning, a laboratory manual (ed. C. Nolan), pp. 4–5. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, USA.
Szczepański T., Orfão A., van der Velden V. H. J., San Miguel J. F. and van Dongen J. J. M. 2001 Minimal residual disease in leukemia patients. Lancet Oncol. 2, 409–417.
Van der Velden V. H., Panzer-Grumayer E. R., Cazzaniga G., Flohr T., Sutton R., Schrauder A. et al. 2007 Optimization of PCRbased minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 21, 706–713.
Van Dongen J. J. M., Seriu T., Panzer-Grümayer R. E., Biondi A., Pongres-Willemse M. J., Corral L. et al. 1998 Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 352, 1731–1738.
Van Dongen J. J. M., Langerak A. W., Brüggemann M., Evans P. A. S., Hummel M., Lavender F. M. et al. 2003 Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-396. Leukemia 17, 2257–2317.
Van Krieken J. H. J. M., Langerak A. W., Macintyre E. A., Kneba M., Hodges E., Garcia Sanz R. et al. 2007 Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 21, 201–206.
Wright D. K. and Manos M. M. 1990 Sample preparation from paraffin embeded tissues. In PCR protocols: a guide to methods and applications (ed.M. A. Innis, D. H. Gelfand, J. J. Snisky and T. J. White), pp. 153–157. Academic Press, San Diego, USA.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cikota, B.M., Tukić, L.J., Tarabar, O.T. et al. PCR-based clonality assessment in patients with lymphocytic leukaemias: a single-institution experience. J Genet 88, 309–314 (2009). https://doi.org/10.1007/s12041-009-0044-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12041-009-0044-8